Toxicity after central versus peripheral lung stereotactic body radiation therapy: A propensity score matched-pair analysis

International Journal of Radiation Oncology Biology Physics

Volumn 91, Issue 1, 2015, Pages 124-132

  Mangona, Victor S ^a   Aneese, Andrew M ^b   Marina, Ovidiu ^a   Hymas, Richard V ^a   Ionascu, Dan ^a,b   Robertson, John M ^a,b   Gallardo, Lori J ^a,b   Grills, Inga Siiner ^a,b  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b OAKLAND UNIVERSITY WILLIAM BEAUMONT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ORGANS; COMPUTERIZED TOMOGRAPHY; DRUG PRODUCTS; RISK ANALYSIS; RISK ASSESSMENT; TOXICITY; TUMORS;

CENTRAL NERVOUS SYSTEMS; COMMON TERMINOLOGY CRITERIA; COMPETING RISKS ANALYSIS; NON SMALL CELL LUNG CANCER; PLANNING TUMOR VOLUME; PROPENSITY SCORE MATCHING; PULMONARY FUNCTION TEST; STEREOTACTIC BODY RADIATION THERAPY;

RADIOTHERAPY;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COUGHING; DEHYDRATION; DYSPHAGIA; EMPYEMA; ESOPHAGITIS; FATIGUE; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; HUMAN; HYPERPIGMENTATION; HYPOPIGMENTATION; INCIDENCE; LUNG DISEASE; LUNG FUNCTION TEST; LUNG METASTASIS; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL PAIN; MYCOSIS; MYOSITIS; NON SMALL CELL LUNG CANCER; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROPENSITY SCORE; RADIATION DERMATITIS; RADIATION INJURY; RADIATION RESPONSE; RADIATION SAFETY; RIB FRACTURE; SKIN INDURATION; SKIN TOXICITY; SOFT TISSUE DISEASE; STEREOTACTIC BODY RADIATION THERAPY; TELANGIECTASIA; THORAX PAIN; TREATMENT OUTCOME; ADVERSE EFFECTS; ALGORITHM; CARCINOMA, NON-SMALL-CELL LUNG; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; COMPUTER ASSISTED RADIOTHERAPY; IMAGE GUIDED RADIOTHERAPY; LUNG NEOPLASMS; MEDIASTINUM; MIDDLE AGED; ORGANS AT RISK; PAIN; PATHOLOGY; PROCEDURES; RADIATION DOSE FRACTIONATION; RADIATION INJURIES; RADIOSURGERY; SEX DIFFERENCE; TUMOR VOLUME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; CARCINOMA, NON-SMALL-CELL LUNG; CHI-SQUARE DISTRIBUTION; DOSE FRACTIONATION; FEMALE; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; MEDIASTINUM; MIDDLE AGED; ORGANS AT RISK; PAIN; PROPENSITY SCORE; RADIATION INJURIES; RADIOSURGERY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, IMAGE-GUIDED; RESPIRATORY FUNCTION TESTS; SEX FACTORS; TUMOR BURDEN; YOUNG ADULT;

EID: 84923115618     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2014.08.345     Document Type: Article

References (19)

1. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995;60:615-622. discussion 622-623.
2. Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: Updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007;2:S94-S100.
3. Grills IS, Mangona VS, Welsh R, et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol 2010;28:928-935.
4. Welsh R, Grills IS, Deraniyagala R, et al. Lobectomy, Wedge Resection, or Stereotactic Radiotherapy (SBRT) for Stage I Non-small Cell Lung Cancer: Which Treatment Yields the Best Outcome? Int J Radiat Oncol Biol Phys 2010;78:S180.
5. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010;303:1070-1076.
6. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006;24:4833-4839.
7. Song SY, Choi W, Shin SS, et al. Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus. Lung Cancer 2009;66:89-93.
8. Corradetti MN, Haas AR, Rengan R. Central-airway necrosis after stereotactic body-radiation therapy. N Engl J Med 2012;366:2327-2329.
9. Chang JY, Balter PA, Dong L, et al. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008;72:967-971.
10. Rowe BP, Boffa DJ, Wilson LD, et al. Stereotactic body radiotherapy for central lung tumors. J Thorac Oncol 2012;7:1394-1399.
11. Joyner M, Salter BJ, Papanikolaou N, et al. Stereotactic body radiation therapy for centrally located lung lesions. Acta Oncol 2006;45:802-807.
12. Nuyttens JJ, van der Voort van Zyp NC, Praag J, et al. Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumors. Radiother Oncol 2012;102:383-387.
13. Bezjak A. Radiation Therapy Oncology Group (RTOG) 0813 protocol: Seamless phase I/II study of stereotactic lung radiotherapy (SBRT) for early stage, centrally located, non-small cell lung cancer (NSCLC) in medically inoperable patients. 2012.
14. Kosanke J, Bergstralh E. Locally Written SAS Macros. Rochester, MN: Mayo Clinic, Departments and Division of Biomedical Statistics and Informatics; 2003.
15. Galerani AP, Grills I, Hugo G, et al. Dosimetric impact of online correction via cone-beam CT-based image guidance for stereotactic lung radiotherapy. Int J Radiat Oncol Biol Phys 2010;78:1571-1578.
16. National Cancer Institute, National Institutes of Health. Common Terminology Criteria for Adverse Events v3.0. Washington, DC: US Department of Health and Human Services; 2006.
17. Creach KM, El Naqa I, Bradley JD, et al. Dosimetric predictors of chest wall pain after lung stereotactic body radiotherapy. Radiother Oncol 2012;104:23-27.
18. Welsh J, Thomas J, Shah D, et al. Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2011;81:91-96.
19. Haasbeek CJA, Lagerwaard FJ, Slotman BJ, et al. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. J Thorac Oncol 2011;6:2036-2043.